-+ 0.00%
-+ 0.00%
-+ 0.00%

Corcept Therapeutics Presented Results From Its DAZALS Study Of Dazucorilant In Patients With ALS At The European Network To Cure ALS 2025 Annual Meeting, DAZALS Did Not Meet Its Primary Endpoint Of Improved Outcome In The Als Functional Rating Scale-revised Compared To Placebo

Benzinga·06/05/2025 10:08:22
Listen to the news
  • DAZALS did not meet its primary endpoint of improved outcome in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to patients who received placebo
  • DAZALS met its secondary endpoint of improved overall survival at week 24 of the study in patients who received 300 mg of dazucorilant compared to patients who received placebo
  • Exploratory analysis at the one-year mark shows continued significant improvement in overall survival between patients who received 300 mg of dazucorilant and those who received placebo only
  • Corcept seeking guidance from United States and European regulators on optimum path forward